Amarin Corporation announced the publication of new data in the Journal of the American Heart Association, detailing a post-hoc analysis from the REDUCE-IT study, which found that Icosapent Ethyl ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth ...

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Cardiovascular (CV) risk reduction is important in patients at high risk for a first ...

After hours: March 24 at 7:12:00 PM EDT Loading Chart for AMRN ...

Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...

In draft guidance, the health technology assessment (HTA) organisation has recommended Vazkepa (icosapent ethyl) as a treatment option for adult patients with high-risk cardiovascular disease and ...

VASCEPA (icosapent ethyl) is indicated to reduce cardiovascular risk in patients with elevated triglyceride levels and established cardiovascular disease. Disclaimer: This is an AI-generated ...